Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics

Capricor Therapeutics, Inc. (CAPR): $4.69

0.01 (+0.21%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add CAPR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#227 of 340

in industry

CAPR Price/Volume Stats

Current price $4.69 52-week high $8.22
Prev. close $4.68 52-week low $2.68
Day low $4.64 Volume 202,200
Day high $4.76 Avg. volume 356,186
50-day MA $5.21 Dividend yield N/A
200-day MA $4.57 Market Cap 149.98M

CAPR Stock Price Chart Interactive Chart >


Capricor Therapeutics, Inc. (CAPR) Company Bio


Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.


CAPR Latest News Stream


Event/Time News Detail
Loading, please wait...

CAPR Latest Social Stream


Loading social stream, please wait...

View Full CAPR Social Stream

Latest CAPR News From Around the Web

Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.

Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years

Over the last month the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) has been much stronger than before, rebounding by...

Yahoo | December 13, 2023

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- --Company Plans to Request a Meeting with FDA in the First Quarter of 2024 to Further Discuss Opportunities for Expedited Approval Pathways-- SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),

Yahoo | December 11, 2023

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 16, 2023

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded. I would now like to turn the conference call over to our host, Mr. AJ Bergmann, Capricor’s […]

Yahoo | November 16, 2023

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku- -Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application Submission- -Conference Call and Webcast Today

Yahoo | November 14, 2023

Read More 'CAPR' Stories Here

CAPR Price Returns

1-mo -0.21%
3-mo -5.06%
6-mo 13.56%
1-year 3.08%
3-year -2.09%
5-year -3.50%
YTD -4.09%
2023 26.68%
2022 31.74%
2021 -14.58%
2020 167.97%
2019 -68.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!